(Q51512202)
Statements
PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer. (English)
1 reference
Y Zhang
1 reference
M Liu
1 reference
H Yang
1 reference
J Wang
1 reference
H Liu
1 reference
X Li
1 reference
J Li
1 reference
J Xu
1 reference
X Li
1 reference
1 January 2014
1 reference
61
1 reference
4
1 reference
461-467
1 reference